XSHG
600739
Market cap2.30bUSD
Oct 09, Last price
10.33CNY
1D
1.97%
1Q
2.28%
Jan 2017
-42.45%
Name
Liaoning Cheng Da Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in Dalian, China, in 1991, Liaoning Cheng Da Co., Ltd. operates a diverse business portfolio both domestically and across international markets. Its extensive activities span four core areas: trading, medicine and healthcare, financial investment, and energy development. The company's trading arm handles a wide array of goods, including textiles, apparel, chemicals, coal, aquatic products, timber, and steel, while also providing medical insurance. Its robust medicine and healthcare division focuses on the research, development, production, and marketing of human and veterinary vaccines. This segment also manages pharmaceutical retail, wholesale, and logistics distribution, offers medical enterprise management consulting, and sells medical equipment. Furthermore, it provides services in medical technology, computer hardware and software development, technology consulting, transfer, and general technical support. In the financial sector, Liaoning Cheng Da Co., Ltd. engages in securities and fund activities, and for energy development, it is involved in oil shale projects.
Key people
Yu Ge
President, Director
Hao Zhu
Chief Financial Officer · since 2018
Sen Li
Vice President · since 2018
Shaohui Pei
Vice President · since 2019
Longxi Quan
Vice President · since 2006
Bin Wang
Vice President
Taihua Wu
Vice President · since 2018
Liqun Wu
Vice President · since 2010
Zhifan Zhang
Vice President · since 2008
Zhanyang Yu
Secretary of the Board · since 2004
Chairman of the Board
Independent Director · since 2015
Hong Yao
Independent Director · since 2016
Liming Zhang
Independent Director · since 2018
Headquarters & legal address
大连市中山区人民路71号
大连市, LN 100000
CN
大连市, LN 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||